ArticleESC heart failure2020
Comparing short-term outcome after implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3®.
Article in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Ten-year follow-up of the first left ventricular assist device implantation program in Chile: a case series.Journal of cardiothoracic surgery · 2026Article
- In Vitro Comparison of Device-Induced Hemolysis, Platelet Defects, and von Willebrand Factor Degradation Between the HeartMate 2 and HeartMate 3 Pumps.Artificial organs · 2025Article
- Preventive catheter ablation for ventricular arrhythmias in patients with end-stage heart failure referred for heart transplantation evaluation: Rationale for and design of the CASTLE-VT trial.European journal of heart failure · 2025Article
- Pregnancy with a Left Ventricular Assist Device: A Narrative Review.Annals of cardiac anaesthesia · 2025Review
- Predictors of long-term success after successful explantation of continuous flow left ventricular assist device support.Interdisciplinary cardiovascular and thoracic surgery · 2024Article
- Hospital Readmissions in Patients Supported with Durable Centrifugal-Flow Left Ventricular Assist Devices.Journal of clinical medicine · 2024Article
- Developments and Challenges in Durable Ventricular Assist Device Technology: A Comprehensive Review with a Focus on Advancements in China.Journal of cardiovascular development and disease · 2024Review
- Heartware ventricular assist device versus HeartMate II versus HeartMate III in advanced heart failure patients: A systematic review and meta-analysis.SAGE open medicine · 2024Review
- Identifying patients at risk: multi-centre comparison of HeartMate 3 and HeartWare left ventricular assist devices.ESC heart failure · 2023Article
- Clinical outcomes of continuous flow left ventricular assist device therapy as bridge to transplant strategy in muscular dystrophy: a single-center study.General thoracic and cardiovascular surgery · 2023Article
- Five-Year Outcome After Continuous Flow LVAD With Full-Magnetic (HeartMate 3) Versus Hybrid Levitation System (HeartWare): A Propensity-Score Matched Study From an All-Comers Multicentre Registry.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Surgical Interventions for Late Aortic Valve Regurgitation Associated with Continuous Flow-Left Ventricular Assist Device Therapy: Experience Gained and Lessons Learned.Life (Basel, Switzerland) · 2022Article
- Evolution of thrombolytic therapy in patients with HeartWare ventricular assist device thrombosis: a single-institutional experience.Interactive cardiovascular and thoracic surgery · 2022Article
- Safety, Mortality, and Hemodynamic Impact of Patients with MitraClip Undergoing Left Ventricular Assist Device Implantation.Journal of cardiovascular translational research · 2022Article
- Article
- The dominant left ventricular assist device: lessons from an era.ESC heart failure · 2021Review
- Creating an impact, not an impression: ESC Heart Failure in its seventh year.ESC heart failure · 2021Article
- GMP-Compliant Radiosynthesis of [Pharmaceuticals (Basel, Switzerland) · 2021Article
- First-in-human high-density epicardial mapping and ablation through a left anterior minithoracotomy in an LVAD patient presenting in electrical storm: a case report.European heart journal. Case reports · 2021Article
- Catheter ablation for atrial fibrillation in patients with end-stage heart failure and eligibility for heart transplantation.ESC heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsCentrifugal continuous flow pumps are currently the state of the art in left ventricular assist device therapy. This study was conducted to compare the results after implantation of the HVAD® and the HeartMate 3®. METHODS AND
resultsWe retrospectively analysed preoperative and post-operative patient data of all 106 patients, who received a HeartMate 3 (HM3) at our centre between 2014 and 2018. A total of 392 patients receiving a sintered HVAD® served as controls. Patient matching was performed for age, sex, Interagency Registry for Mechanically Assisted Circulatory Support level at the time of implant, perioperative right heart failure, and implantation strategy, that is, bridge to transplant or destination therapy, as well as preoperative renal function, that is, as indicated by serum creatinine levels. A total of 79 matched pairs could be identified. During a median follow-up of 15.3 months (range: 0-30 months), 23 (29.1%) and 19 (24.1%) patients died in the HVAD and HM3 groups, respectively, with a hazard ratio for mortality of 0.84 [95% confidence interval (CI): 0.46-1.54; P = 0.568]. Freedom from cerebrovascular events did not differ significantly between study groups, with a hazard ratio of 0.57 (95% CI: 0.23-1.45; P = 0.241). The risk of driveline infection was significantly lower in the HM3 (n = 33) than in the HVAD (n = 55) group (hazard ratio = 0.54; 95% CI: 0.35-0.84; P = 0.006). Eight HVAD, but no HM3, patients developed a pump thrombosis during follow-up (P = 0.148).
conclusionsPerformance of both currently used centrifugal left ventricular assist device systems is comparable in terms of short-term patient survival and freedom from cerebrovascular events. In our single-centre experience, HM3 patients less frequently develop driveline infections and no pump thrombosis, which requires further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.